Camp Fimfo Texas Hill Country is kicking off the season with two bold additions designed to elevate every guest's experience: the adrenaline-pumping Guadalupe Glider Zipline, opening Memorial Day Weekend, and the stunning Hilltop Hideaway pool and pool deck, which opened in March 2025. https://mma.prnewswire.com/media/2692227/Northgate_Resorts_Hilltop_Hideaway_at_Camp_Fimfo.jpg “At Camp Fimfo, we're always looking for new ways to help […]

LOS ANGELES, May 21, 2025 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the appointment of Benjamin Greenberg, MD, MHS, to its Scientific Advisory Board. Dr. Greenberg will assist in evaluating the clinical development of Trethera's lead asset, TRE-515, in demyelinating autoimmune

Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board GlobeNewswire May 21, 2025 LOS ANGELES, May 21, 2025 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the appointment of Benjamin Greenberg, MD, MHS, to its

IOVA Investors with Losses Encouraged to Contact Hagens Berman Biotechnology firmIovance Biotherapeutics, Inc. (NASSAQ: IOVA) is facing a securities class action lawsuit in the Northern District of California, alleging that the company misled investors about its growth potential and ability to capitalize on demand for its cancer treatments. The case, Farberov v. Iovance Biotherapeutics, Inc.,

(NASDAQ:ALMS), SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN

CEDARVILLE, OHIO, May 21, 2025 (GLOBE NEWSWIRE) — As artificial intelligence (AI) and data science transform industries, redefine professions and raise urgent ethical questions, universities are racing to prepare students for a future shaped by intelligent machines and vast data ecosystems. In response to this global shift, Cedarville University has launched a new academic initiative

NEW AI Courses Bring Competitive Advantage to College Students Ohio's Cedarville University Announces NEW AI Initiative GlobeNewswire May 21, 2025 CEDARVILLE, OHIO, May 21, 2025 (GLOBE NEWSWIRE) — As artificial intelligence (AI) and data science transform industries, redefine professions and raise urgent ethical questions, universities are racing to prepare students for a future shaped by

Alumis Completes Merger with ACELYRIN Establishes leading clinical stage biopharma company with differentiated portfolio of therapies and strong balance sheet GlobeNewswire May 21, 2025 SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it

Finally, a highly effective and extra gentle eye cream for the area aroundyour dry and sensitive eyes! — Scope Health launches theOPTASE® LIFE Sensitive Eye Daily Renewal Cream, with an eye doctor and dermatologist-approved formula designed for use around dry and sensitive eyes with gentle, clean ingredients – formulated without harmful chemicals and toxins, such

TNL Mediagene (Nasdaq: TNMG) (the “Company”), a Tokyo-based next-generation digital media and data group in Asia, announces its recent feature interview on McNallie Money. Co-Founder & CEO Joey Chung joins host Bryce McNallie to discuss the Company's recently announced strong FY2024 performance of consolidated revenue of $48.5million, gross profit of $17.7million, near break-even Adjusted EBITDA